Presence of sHLA-E in patient sera correlates with disease activity in vasculitis (WG and MPA)
| Group . | Sera, no. tested (no. of patients) . | sHLA-E detected . | CRP, mg/L . | sIL-2Rβ, μg/mL . | IL-8, pg/mL . | VEGF, pg/mL . |
|---|---|---|---|---|---|---|
| Total vasculitis, WG and MPA | 22 (10) | — | — | — | — | — |
| Active phase | 11 | 9* | 143 ± 69*† | 5.6 ± 3.2*† | 585 ± 73* | 1055 ± 265*† |
| Inactive phase | 11 | 3 | 3.4 ± 0.4 | 2.1 ± 0.9† | ≤30 | 214 ± 104 |
| Controls | 9 (9) | 0 | ≤3.2 | 0.65 ± 0.36 | ≤30 | 209 ± 18 |
| Group . | Sera, no. tested (no. of patients) . | sHLA-E detected . | CRP, mg/L . | sIL-2Rβ, μg/mL . | IL-8, pg/mL . | VEGF, pg/mL . |
|---|---|---|---|---|---|---|
| Total vasculitis, WG and MPA | 22 (10) | — | — | — | — | — |
| Active phase | 11 | 9* | 143 ± 69*† | 5.6 ± 3.2*† | 585 ± 73* | 1055 ± 265*† |
| Inactive phase | 11 | 3 | 3.4 ± 0.4 | 2.1 ± 0.9† | ≤30 | 214 ± 104 |
| Controls | 9 (9) | 0 | ≤3.2 | 0.65 ± 0.36 | ≤30 | 209 ± 18 |
sHLA-E was detected by Western blot assays as described in “Materials and methods.” Sera from patients or healthy controls were assayed for the sIL-2Rα, IL-8, and VEGF by ELISA assays. Data are shown as means ± SD.
— indicates not applicable.
P < .01 versus inactive phase.
P < .01 versus controls (sera from healthy donors).